TP53 and cancer: To verify the results, we evaluated the core p53-effector lncRNA levels in independent bulk (n = 10 TCGA cancer types) and single-cell (n = 24 cancer cell lines) RNA-seq (scRNA-seq) data across cancer types where cells/tissues have p53WT or p53 loss-of-function (p53LOF) mutations/truncating alterations, or the cells were treated with either p53-activating stimuli or vehicle control, respectively.